ClinicalTrials.gg
CompletedNCT01635751GLA5PR-101Updated Jan 28, 2013

A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects

A Phase 1 interventional study of Pregabalin and Pregabalin in Healthy, sponsored by GL Pharm Tech Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-28.

Sponsored by GL Pharm Tech Corporation · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GLA5PR GLARS tablet 150mg and Lyrica Capsule 75mg.

GLA5PR GLARS tablet 150mg is a new once-a-day formulation which is made by GL Pharm Tech corporation.

GLARS(Geometrically Long Absorption Regulated System) is new solution to sustained absorption by extending the absorption Site.

To overcome the shortcomings of the currently existing sustained release drug delivery technologies the investigators have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. The investigators coined this "Geometrically Long Absorption Regulated System(GLARS)".

Read the detailed description

Basically, this system is a triple-layered tablet, comprised of upper and lower layers that swell and draw a sufficient amount of water, plus a highly water - soluble middle layer that rapidly draw water into the tablet core simultaneously.

The water drawn into the tablet (about 3 to 4 times the weight of the tablet itself) functions as an additional media which enables additional and later drug release out of the dosage form. This serves to overcome the shortage of surrounding media that has been reported to be one of the key reasons for malabsorption of a drug in colon.

As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and controls drug release.

At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release.

This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release irrespective of degree of gastrointestinal motility.

02

Conditions studied

  • Healthy

Keywords

  • Pregabalin
  • GLARS
03

In context

Lead sponsor

GL Pharm Tech Corporation is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20\~45 years old, Healthy Adult Male Subject
  • ≥ 50kg(Body Weight) and Ideal Body Weight ≤ ±20%

Exclusion criteria

Exclusion Criteria:

  • or AST > 1.25(Upper Normal Range)
  • Total > 1.5 (Upper Normal Range)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    GLA5PR GLARS tablet 150mg(fasted)

    Drug: Pregabalin

  • Experimental
    GLA5PR GLARS tablet 150mg(after high fat meal)

    Drug: Pregabalin

  • Active comparator
    Lyrica Capsule 75mg(fasted)

    Drug: Pregabalin

Interventions

  • GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)

  • GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)

  • Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)

06

What researchers measure

Primary outcomes

  1. Cmax

    Pharmacokinetic of Pregabalin

    Time frame: 36hrs

  2. Tmax

    Pharmacokinetic of Pregabalin

    Time frame: 36hrs

  3. AUC0-36h

    Pharmacokinetic of Pregabalin

    Time frame: 36hrs

  4. AUC0-∞

    Pharmacokinetic of Pregabalin

    Time frame: 36hrs

  5. CL/F

    Pharmacokinetic of Pregabalin

    Time frame: 36hrs

  6. Vd/F

    Pharmacokinetic of Pregabalin

    Time frame: 36hrs

  7. T1/2

    Pharmacokinetic of Pregabalin

    Time frame: 36hrs

Secondary outcomes

  1. Safety Monitoring

    Adverse Event, Vital sign, 12-lead ECG, Laboratory test

    Time frame: 23 days

07

Study locations

1 site
  • The Catholic University of Korea, Seoul St.Mary's Hospital
    Seochogu, Seoul 137-701, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2012
First posted
Jul 10, 2012
Start
Oct 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Jan 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01635751
Lead sponsor
GL Pharm Tech Corporation
Responsible party
Sponsor
First posted
Jul 10, 2012
Start date
Oct 2012
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Jan 28, 2013

Study contacts

Dong-seok Yim
principal investigator · The Catholic University of Korea

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion